Publications

BibTex format

@article{Kenny:2022:10.1111/ecc.13747,
author = {Kenny, L and Beresford, M and Brown, I and Misra, V and Kristeleit, H},
doi = {10.1111/ecc.13747},
journal = {European Journal of Cancer Care},
title = {Eribulin for the treatment of advanced breast cancer: A prospective observational registry study},
url = {http://dx.doi.org/10.1111/ecc.13747},
volume = {31},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Methods:This observational multicentre registry study enrolled 76 patients with locally advanced/metastatic breast cancer who had ≤2 prior chemotherapeutic regimens for advanced disease. Eribulin was administered at a 1.23 mg/m2 dose (days 1 and 8 of every 21-day cycle). Adverse events (AEs) were monitored and effectiveness was assessed per local practice.Results:AEs occurred in 98.7% of patients; 88.2% had eribulin-related AEs. The most common AEs were fatigue (64.5%), alopecia (36.8%), nausea (35.5%) and constipation (30.3%). Serious AEs occurred in 42.1% of patients. The most common grade 3/4 AEs were neutropenia (9.2%), febrile neutropenia (9.2%), dyspnoea (5.3%) and pleural effusion (5.3%). No fatal AEs occurred. Dose reductions occurred in 31.6% of patients, 42.1% experienced dose delays and 9.2% discontinued due to worsening condition. There were complete responses in 2.6% and partial responses in 15.8% of patients. Median time to progression and overall survival were 4.0 and 8.3 months, respectively.Conclusion:Eribulin was well tolerated in real-world clinical practice, comparable to safety and effectiveness reported in other clinical trials.
AU  - Kenny,L
AU  - Beresford,M
AU  - Brown,I
AU  - Misra,V
AU  - Kristeleit,H
DO  - 10.1111/ecc.13747
PY  - 2022///
SN  - 0961-5423
TI  - Eribulin for the treatment of advanced breast cancer: A prospective observational registry study
T2  - European Journal of Cancer Care
UR  - http://dx.doi.org/10.1111/ecc.13747
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000879338300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/100796
VL  - 31
ER  -

Download

DrLauraKenny

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)